Frazier Life Sciences announced a successful close of its twelfth venture fund, raising $1.3 billion to support early-stage biotech companies amid a challenging investment climate. Despite headwinds including funding reductions, tariff threats, and regulatory uncertainties, sustained capital influx from leading firms like Frazier underscores continued investor confidence in innovative therapeutic development. Complementary funding announcements emerged across med-tech and biopharma sectors, highlighting ongoing capital deployment to fuel scientific advancement and commercialization efforts.